Australian Committee Wants HTA Review To Begin Early In 2023
At its next meeting, the Australian committee responsible for reviewing the country's health technology assessment system will discuss feedback from stakeholders, including the pharmaceutical industry, on the draft terms of reference for the review.
You may also be interested in...
Drug industry group Medicines Australia says that the review of the health technology assessment system must ensure that the real impact and benefits of new products for patients are taken into account in reimbursement decisions. Other areas to be explored include the use of real-world data and managing clinical and economic uncertainty.
Industry representatives told a House of Lords committee about continuing Brexit-related problems such as the extra work involved in checking compliance with the EU Falsified Medicines Directive and the drawbacks of a proposed “dual regulatory regime.”
The Medicines and Healthcare products Regulatory Agency says that the fee increases to be introduced on 1 April, along with 18 new fees, are necessary for its long-term financial sustainability and its ability to provide a “responsive, innovative and efficient regulatory service.”